Anixa Biosciences, Inc. ANIX
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 6.59% | 17.31% | 17.42% | 12.96% | 10.08% |
| Total Depreciation and Amortization | 8.33% | 26.67% | 12.12% | -2.70% | -10.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.10% | -23.71% | -14.03% | -23.41% | -24.04% |
| Change in Net Operating Assets | -98.86% | -9,000.00% | -170.79% | -71.10% | 156.47% |
| Cash from Operations | -7.76% | 10.78% | 13.25% | 2.21% | 18.29% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -59.46% | -82.97% | -50.50% | 13.80% | 80.36% |
| Cash from Investing | -59.46% | -82.97% | -50.50% | 13.80% | 80.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 163.08% | 1,721.23% | -27.60% | -30.74% | -44.83% |
| Repurchase of Common Stock | -- | -- | 90.91% | 90.91% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,281.25% | -- | 169.45% | -- | 111.51% |
| Cash from Financing | 156.39% | 1,936.33% | 250.84% | -33.24% | -43.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -135.93% | -147.32% | 798.18% | -107.58% | 113.68% |